

Haematologica
HAEMATOL/2020/249060
Version 1

To target the untargetable: elucidation of synergy of APR-246 and
azacitidine in TP53 mutant MDS/AML

David A. Sallman

Disclosures: 1. I have received no support relevant to the current manuscript. 2. For support outside the submitted work: I have received research funding from Celgene and Jazz; Advisory Board from Agios, Celyad and Intellia; Speakers Bureau from Abbvie, Agios, Incyte, and Novartis. 3. I do not have any patents broadly relevant to the current manuscript.